StockIQ.techBristol-Myers Squibb Company (BMY) Stock Analysis
Free AI-powered analysis and research for Bristol-Myers Squibb Company stock
Sector: Healthcare
BMY snapshot
Data as of 16 Oct 2026 close. Updated daily.
Bristol-Myers Squibb Company scores 68/100 on StockIQ's model, which reads as positive signals overall. The price is above its 200-day average and at 66% of its 52-week range, up 36.9% over the past year. Latest reported figures show a profit margin of 18.9%, return on equity of 46.6% and revenue growth of +5.7%.
What is driving the score
- RSI Neutral: +5
- Strong Downtrend: -10
- MACD Bullish: +8
- Low P/E (12.7): +10
- Good Profit Margin (18.9%): +5
- High Debt (2.02 D/E): -10
- Excellent ROE (46.6%): +8
- High P/B (5.27): -5
- Above MA200: +4
- Strong Momentum (+36.9% over 1 year): +3
Automated, general information only – not financial advice. Scores can be wrong. How the score works
Full BMY report
Bristol-Myers Squibb Company (BMY) is listed in the Healthcare sector. The snapshot on this page updates daily; run a full report for the complete breakdown.
Analyze BMY Now →📰 Latest Update
Bristol Myers Squibb’s 4.2% Dividend Yield Comes With a Trade-Off Investors Should Know
Fri, October 16, 2026 at 5:45 PM UTC 2 min read
Bristol Myers Squibb (BMY) recently announced a 4.2% dividend yield, which may attract income-focused investors. However, analysts caution that this high yield comes with potential trade-offs, including concerns about the company's future growth prospects and the sustainability of its dividend payments. Investors should carefully weigh these factors before making investment decisions, as the balance between yield and growth is crucial for long-term returns.